Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OCUL | CLUSTER | neutral | 3/10 | Four OCUL insiders, including the Chief Scientific Officer and Chief Strategy Officer, sold a total of $322K in open-mar | Aug 26, 2026 |
| IMRX | PRESS-RELEASE | neutral | 4/10 | Immuneering issued a press release commenting on the recent FDA approval of a new second-line pancreatic cancer treatmen | Aug 26, 2026 |
| PGEN | 144 | neutral | 3/10 | Director Jeffrey Kindler filed a Form 144 to sell 185,000 shares of Precigen (PGEN) at an estimated aggregate value of $ | Aug 26, 2026 |
| BMRA | 8-K | bearish | 7/10 | Biomerica entered into a securities purchase agreement on August 20, 2026, to sell 1,393,705 shares at $1.60/share for ~ | Aug 26, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K on August 26, 2026, disclosing the allotment of 4,110 equity shares (Re. 1 par value) to | Aug 26, 2026 |
| BKHA | 8-K | neutral | 4/10 | Black Hawk Acquisition Corp. (BKHA), a SPAC, issued a convertible promissory note to its sponsor for up to $300,000 to f | Aug 26, 2026 |
| RVMD | 8-K | bullish | 8/10 | Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on Augus | Aug 26, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at | Aug 26, 2026 |
| ROIV | PRESS-RELEASE | bullish | 6/10 | Priovant Therapeutics (a Roivant company) published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib | Aug 26, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting that Maya Martinez-Davis, President US, acquired 9.221 notional American Depositary Share | Aug 26, 2026 |
| ADXN | 6-K | bearish | 6/10 | Addex Therapeutics raised $2.8 million gross proceeds via an ATM equity offering with H.C. Wainwright, selling 437,869 A | Aug 26, 2026 |
| ONC | 8-K | neutral | 2/10 | BeOne Medicines filed its STAR Market interim report (H1 2026) in China, disclosing R&D spending breakdown by key produc | Aug 26, 2026 |
| BHVN | 8-K | bullish | 7/10 | Biohaven entered into a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform | Aug 26, 2026 |
| LNTH | PREM14A | bullish | 7/10 | Lantheus Holdings has filed a PREM14A preliminary proxy statement for the proposed acquisition by Curium US Holdings LLC | Aug 26, 2026 |
| ANL | 6-K | mixed | 6/10 | Adlai Nortye Group Ltd. filed a 6-K convening an Extraordinary General Meeting (EGM) on September 30, 2026. The most mat | Aug 26, 2026 |
| SMMT | 8-K | bullish | 7/10 | Partner Akeso announced positive topline results from the Phase III HARMONi-GI1 study evaluating ivonescimab plus chemot | Aug 26, 2026 |
| RADX | 6-K | neutral | 4/10 | Radiopharm Theranostics dosed the first patient in the second cohort (70 mCi dose) of its Phase 1/2a trial for RV-01 (Be | Aug 26, 2026 |
| GYRE | 8-K | neutral | 4/10 | Gyre Therapeutics filed an 8-K furnishing an updated corporate presentation under Item 7.01. The presentation highlights | Aug 26, 2026 |
| GEVO | 8-K | neutral | 3/10 | Gevo appointed Greg Hanselman as Chief Operating Officer, effective August 20, 2026, and expanded the roles of Kyle Jame | Aug 26, 2026 |
| OPTH | EFFECT | bullish | 7/10 | The SEC declared Optimi Health Corp.'s F-1 registration statement effective on August 25, 2026, clearing the way for its | Aug 26, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai Immunotherapeutics reported H1 2026 results with revenue up to $949K (from $773K YoY) but gross loss widened to $ | Aug 26, 2026 |
| SNYR | 8-K | bearish | 9/10 | Synergy CHC Corp. received a Notice of Acceleration from its lender ACP Agency, LLC, declaring all ~$18.9 million in out | Aug 26, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess | Aug 26, 2026 |
| INDP | EFFECT | bearish | 7/10 | The SEC declared effective Indaptus Therapeutics' S-3 registration (File No. 333-298388) on August 25, 2026, covering up | Aug 26, 2026 |
| SXTP | EFFECT | bearish | 6/10 | 60 Degrees Pharmaceuticals' S-3 shelf registration (File No. 333-298349) became effective on August 25, 2026. This allow | Aug 26, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem filed a request for extrajudicial reorganization (a Brazilian restructuring proceeding) on August 24, 2026, afte | Aug 26, 2026 |
| LYEL | CLUSTER | neutral | 4/10 | Three top executives at Lyell Immunopharma (CEO, CSO, COO) sold a combined $187K in stock on the same day (Aug 21, 2026) | Aug 26, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Two Liquidia insiders, the Chief Medical Officer and a Director, sold a combined $5.03M in open-market stock over three | Aug 26, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Two Teva insiders, a director and an EVP, sold a combined $696K in open-market sales over a one-week window. The EVP's $ | Aug 26, 2026 |
| RVMD | CLUSTER | neutral | 3/10 | Two insiders at Revolution Medicines, General Counsel Jeff Cislini and Director Mark Goldsmith, sold a combined ~$22.5M | Aug 26, 2026 |